Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 908-919

  Pajtler, Kristian W ^a   Rebmann, Vera ^a   Lindemann, Monika ^a   Schulte, Johannes H ^a,b   Schulte, Stefanie ^a   Stauder, Michael ^a   Leuschner, Ivo ^c   Schmid, Kurt Werner ^a   Köhl, Ulrike ^d   Schramm, Alexander ^a   Eggert, Angelika ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cytotoxic lymphocytes; neurotrophin receptor; NK cells; spontaneous regression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A;

ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY; UPREGULATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, TRKA; TISSUE ARRAY ANALYSIS;

EID: 84878819086     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28096     Document Type: Article

References (50)

1. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16. (Pubitemid 37328872)
2. Ollert MW, David K, Schmitt C, et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A 1996; 93: 4498-503. (Pubitemid 26144315)
3. Prigione I, Corrias MV, Airoldi I, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004; 1028: 69-80. (Pubitemid 40361811)
4. Huenecke S, Zimmermann SY, Kloess S, et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 2010; 33: 200-10.
5. Kloess S, Huenecke S, Piechulek D, et al. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 2010; 40: 3255-67.
6. Cheung NK, Modak S,. Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002; 8: 1217-23. (Pubitemid 34517661)
7. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-34.
8. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54. (Pubitemid 23084339)
9. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001; 61: 1314-9. (Pubitemid 34292549)
10. Eggert A, Ikegaki N, Liu X-G, et al. Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene 2000; 19: 2043-51. (Pubitemid 30229417)
11. Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of Trk-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759-67.
12. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16: 1265-9. (Pubitemid 28175738)
13. Brodeur GM, Castle VP. In:, Hickman JA, Dive C, eds. Apoptosis and cancer chemotherapy. New Jersey: Humana, 1999. 305-18.
14. Papac RJ,. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998; 12: 571-8. (Pubitemid 29011990)
15. Bolande RP,. A natural immune system in pregnancy serum lethal to human neuroblastoma cells: a possible mechanism of spontaneous regression. Perspect Pediatr Pathol 1992; 16: 120-33.
16. Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009; 15: 3244-50.
17. Martin RF, Beckwith JB,. Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 1968; 3: 161-4.
18. Carlson LM, Pahlman S, De Geer A, et al. Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells. Cell Res 2008; 18: 398-411. (Pubitemid 351333903)
19. Schulte JH, Schramm A, Klein-Hitpass L, et al. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 2005; 24: 165-77. (Pubitemid 40143876)
20. Eggert A, Ho R, Ikegaki N, et al. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification. Med Pediatr Oncol 2000; 35: 623-27.
21. Schramm A, Schulte JH, Klein-Hitpass L, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005; 24: 7902-12. (Pubitemid 41715196)
22. Eggert A, Brodeur GM, Ikegaki N,. A relative quantitative RT-PCR protocol for TrkB expression in neuroblastoma using GAPD as an internal control. Biotechniques 2000; 28: 681-91. (Pubitemid 30198604)
23. Riley JL, Blair PJ, Musser JT, et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol 2001; 166: 4943-8. (Pubitemid 32280704)
24. Lindemann M, Bohmer J, Zabel M, Grosse-Wilde H,. ELISpot: a new tool for the detection of nickel sensitization. Clin Exp Allergy 2003; 33: 992-8. (Pubitemid 36851251)
25. Lindemann M, Saure C, Klinkenbusch H, et al. Alloreactivity in recipients prior to and post living kidney and liver transplantation. Scand J Immunol 2011; 73: 344-5.
26. Lindemann M, Virchow S, Ramann F, et al. The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett 2001; 495: 82-6. (Pubitemid 32367978)
27. Facchetti P, Prigione I, Ghiotto F, et al. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma. Cancer Immunol Immunother 1996; 42: 170-8. (Pubitemid 26151615)
28. Wolfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005; 54: 400-6. (Pubitemid 40238934)
29. Eggert A, Grotzer MA, Ikegaki N, et al. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002; 62: 1802-8. (Pubitemid 34408506)
30. Eggert A, Sieverts H, Ikegaki N, et al. p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of trkA. Med Pediatr Oncol 2000; 35: 573-76.
31. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78. (Pubitemid 37324571)
32. Koster J., R2: microarray analysis and visualization platform Amsterdam, 2008.
33. Okada K, Komuta K, Hashimoto S, et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000; 6: 3560-4.
34. Lampson LA, Fisher CA, Whelan JP,. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130: 2471-8. (Pubitemid 13086807)
35. Ponzoni M, Casalaro A, Lanciotti M, et al. The combination of interferon and tumor necrosis factor causes a rapid and extensive differentiation of human neuroblastoma cells. Cancer Res 1992; 52: 931-39.
36. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005; 24: 4634-44. (Pubitemid 41032601)
37. Drew PD, Lonergan M, Goldstein ME, et al. Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol 1993; 150: 3300-10. (Pubitemid 23129709)
38. Vertuani S, De Geer A, Levitsky V, et al. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 2003; 63: 8006-13. (Pubitemid 37466739)
39. Wang JH, Smolyar A, Tan K, et al. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell 1999; 97: 791-803. (Pubitemid 29278052)
40. Altomonte M, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993; 53: 3343-8. (Pubitemid 23223307)
41. Kis-Toth K, Szanto A, Thai TH, et al. Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response. J Immunol 187: 1222-34.
42. Farrell PJ, Broeze RJ, Lengyel P,. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature 1979; 279: 523-5. (Pubitemid 9195259)
43. D'Cunha J, Ramanujam S, Wagner RJ, et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 1996; 157: 4100-8. (Pubitemid 126449322)
44. Kabouridis PS, Pimentel TA, Brancaleone V, et al. Distinct localization of T cell Agrin during antigen presentation-evidence for the expression of Agrin receptor(s) in antigen-presenting cells. FEBS J 2012; 279: 2368-80.
45. Ljunggren HG, Karre K,. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-44. (Pubitemid 20198988)
46. Lanier LL,. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74. (Pubitemid 40563170)
47. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503-10. (Pubitemid 351560519)
48. Groth A, Kloss S, von Strandmann EP, et al. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun 2011; 3: 344-54.
49. Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-68. (Pubitemid 39411093)
50. Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-71. (Pubitemid 32867877)